Dec. 26, 2024 Newsom hopes to use CalRx to produce generic versions of insulin, naloxone and other drugs for an at-cost price, he announced in 2023 alongside a $50-million contract with a ...

An U.S. District Court recently ruled against Zydus and Lupin, finding Astellas's patent for Myrbetriq was not invalid. Both ...

President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers ... undermine their ability to do business with the US, especially ...